SHANGHAI, April 4, 2026 /PRNewswire/ -- From April 2 to 31, the Assembly Character Toys brand Blokees made its debut at the 2026 Thailand Toy Expo. Blokees unveiled its two major categories — Blokees Model Kits and Blokees Wheels, highlighting a diverse product matrix of more than 300 products across 17 globally recognized IPs, including Ultraman, Transformers, DC, Evangelion, Naruto, Minions, Jurassic World, Hatsune Miku, and Hero Infinity. Four new model kits also made their global debut, emerging as key highlights of the event.

Mario Maurer attended the opening ceremony of Blokees Thailand Toy Expo as a special guest and engaged in interactive exchanges with consumers.

In the Blokees Model Kits category, Blokees exhibited its Champion, Legend, and Fantastic Series, featuring popular IPs such as Transformers, DC, Mega Man, Saint Seiya, Evangelion, and Naruto. More than 50 products were presented to consumers. Among them, four newly launched items—including Blokees Saint Seiya-Champion Class-12-Phoenix Ikki, Blokees Saint Seiya-Champion Class-14-Andromeda Shun, Blokees DC-Champion Class 05-Batman (HUSH), and Blokees DC-Champion Class 06-Catwoman (Hush)—drew strong interest from fans.

Blokees also highlighted its HERO5 and HERO10 series, featuring well-known IPs including Transformers, Saint Seiya, and Naruto, catering to consumers of hero-themed collectible models.

The DaaLaMode series introduced a range of products inspired by popular IPs such as Hatsune Miku, appealing to female consumers. Meanwhile, the TERRAVENTURE series presented nature and creature-themed model kits based on Jurassic World, further expanding Blokees' offerings across different consumer segments.

In the Blokees Wheels category, which integrates construction, play, and customization, products are organized into the C, E, and S series. The lineup includes IP-based offerings from Transformers, Ultraman, and Batman, with upcoming collaborations featuring Fast & Furious and Ford.

In addition, Blokees highlighted its global consumer ecosystem, BFC (Blokees Family Creator). Selected works from 2025 The 3rd BFC Creation Contest Stellar Season were exhibited in Thailand for the first time, reflecting strong user creativity and engagement. 2026 The 4th BFC Creation Contest Season of Awakening has officially launched, further encouraging global participation.

Under its "Universally appealing, Stepwise pricing, Globally promoting" strategy, Blokees continues to expand across Southeast Asia, Europe, North America, and Latin America. Thailand is rapidly becoming a strategic hub in its regional expansion, as the company strengthens both product innovation and community-driven growth worldwide.

上海2026年4月3日 /美通社/ -- 近日，全球領先的 「AI+器官芯片」驅動的科技平台企業耀速科技（Xellar Biosystems）宣佈完成超 2 億元人民幣 A 輪融資。本輪融資由國壽股權獨家領投，老股東晶泰科技、雅億資本、君聯資本持續加碼。本輪資金將重點投入於構建以人源化模型與機制研究為核心的下一代生物智能基礎設施，包括拓展器官芯片疾病模型體系，建立可規模化運行的機制研究平台，並持續進行高通量、標準化的真實生物數據採集與積累。在此基礎上，公司將加速推進以專有 3D 濕實驗數據為核心驅動的 AI 平台建設與合作，融合多模態數據建模、計算機視覺與知識圖譜，實現「數據生成—機制解析—模型訓練—實驗驗證」 的閉環飛輪，逐步構建具備動態表徵與預測能力的「真實世界數據（Real World Data）+虛擬細胞（Virtual Cell）」 為基礎的 3D Bio Intelligence 體系，實現對複雜生物過程的數字化重建與機制推演。

耀速科技由哈佛科學家團隊創立，是一家以器官芯片（Organ-on-a-Chip）為核心，深度融合人工智能、自動化與高通量實驗系統的 AI for 3D Biology 平台公司，致力於通過高保真模擬人類生理與疾病狀態，重構下一代藥物研發新範式。公司平台可在更接近真實人體的條件下，實現標準化、可重複、可量化的數據生成，並通過 AI 模型持續學習與迭代，顯著提升藥物研發的預測能力與研發效率。

晶泰科技作為耀速科技的戰略投資方，在 AI+機器人賦能新藥研發領域擁有行業領先技術和豐富的成功經驗，已與耀速科技在 AI+器官芯片驅動的藥物篩選和藥效評估領域展開合作並取得初步成果。雙方基於各自平台的技術優勢，將體外複雜模型與 AI 藥物研發技術融合，以更接近真實人體反應的類器官模型和器官芯片等技術，實現更加精確高效的藥物表型篩選與關鍵藥效驗證，助力晶泰科技發現、設計、交付更具臨床潛力的藥物分子。雙方還進一步整合器官芯片技術與機器人自動化實驗，開發新一代高通量藥物篩選與表型技術，打通智能算法與機器人實驗的數據閉環，進一步提高藥物發現的效率與成功率 ，廣泛賦能新一代創新藥研發，為行業創造價值。

目前，耀速科技已與多家全球頭部藥企、消費健康與美妝集團建立長期合作關係，相關業務在過去一年中保持高速增長。公司在藥物安全性評價、疾病模型構建、化合物功效驗證等多個關鍵應用場景實現穩定落地，逐步形成以平台能力、標準體系與數據資產為核心的可持續商業模式。

在監管與國際標準層面，耀速科技近期取得重要進展。公司器官芯片平台從 2023 年開始與 3Rs 組織和 FDA 開展合作，並於今年一月正式被美國食品藥品監督管理局（FDA）接收進入其創新科學與技術推進計劃（ISTAND，Innovative Science and Technology Approaches for New Drugs）的評審通道，有望成為全球首批獲得 FDA 科學認可與資格認定的藥物開發工具（Drug Development Tool，DDT）。在該路徑下，相關技術一旦完成監管層面的驗證，將可被藥企直接作為合規工具用於新藥研發，並進入 IND 申報及後續開發流程，顯著降低藥物研發中的不確定性與重複實驗成本。這一進展標誌著耀速科技的平台能力正從研發工具層面，向監管認可的基礎設施級能力加速演進。

本輪融資完成後，耀速科技將持續加大在人工智能與計算團隊建設上的投入，推動多模態生物數據建模、預測模型及大模型能力的協同發展。同時，公司將與晶泰科技深度合作，推進自動化實驗平台的工業化落地，實現器官芯片實驗執行與數據採集的高度標準化與規模化，並系統性構建器官芯片與疾病機制、藥效毒性及生物通路關聯的知識圖譜，為下一階段更大規模的智能決策與管線共建奠定數據基礎。

晶泰科技董事局主席溫書豪表示：作為老股東，我們見證了耀速團隊從技術理念到平台落地，再到商業驗證的快速跨越。近年來，FDA 對器官芯片的重視與認可不斷提升，這一技術有望成為主流研發方式之一。而當器官芯片與 AI、自動化深度融合，將真正構築起下一代藥物研發的基礎系統。我們持續加碼，正是基於對其平台戰略價值與商業化執行力的高度信心，也期待雙方在智能研發生態中實現更深層次的協同。

耀速科技創始人兼 CEO 謝鑫表示：衷心感謝新老股東對耀速科技的認可與大力支持。本輪融資是對我們 「AI for 3D Biology」平台戰略和團隊執行力的重要背書。融資完成後，我們將全力投入到 AI 計算團隊擴建、自動化體系的規模化落地以及多模態知識圖譜的構建中，持續夯實我們的技術壁壘。與中美藥監機構同步的合作進展，標誌著我們的平台正邁向監管認可的行業基礎設施。我們將攜手合作夥伴，加速推進 「3D Bio Intelligence」在新藥研發各環節的深入應用，切實降低研發成本與風險，為全球患者帶來更多突破性療法。

國壽股權公司表示：我們非常看好耀速科技在 「AI+器官芯片」領域的創新佈局與領先優勢。其技術平台不僅具備高度工程化和規模化的潛力，更在監管認可路徑上取得了實質性突破。我們期待陪伴耀速成長為全球藥物研發新範式的關鍵推動者，助力中國生物科技源頭創新走向世界。

君聯資本表示：耀速科技具備全球頂尖的器官芯片與 AI 、高通量濕實驗結合的技術平台。團隊兼具前沿科學洞察、工程化能力和商業落地韌性，在器官芯片產品、國際科學監管機構合作和行業標準推動、頭部藥企合作等方面不斷突破。君聯資本從天使輪以來多輪持續追加投資，看好公司平台能力和商業價值的加速釋放。

雅億資本創始合夥人劉翀表示：耀速科技將高仿真器官芯片的自動化實驗體系與多模態 AI 深度融合，打通了 「實驗—模型—數據—預測」 的全鏈路閉環，推動藥物研發向數據與智能驅動的範式升級。公司憑借紮實的平台能力，已獲得多家全球頭部企業的認可與合作，並在 FDA 監管路徑上取得關鍵進展，充分驗證了其技術的科學性、穩定性與應用價值。我們非常高興持續支持耀速科技，期待其將這一平台打造為全球藥物研發體系中標準化、可信賴的關鍵基礎設施。

關於耀速科技

耀速科技 2021 年底創立於美國波士頓，是全球首家利用器官芯片結合高內涵三維（3D）細胞成像，計算機視覺（CV）和人工智能（AI）進行藥物發現和精準醫學研究的 「3D Bio Intelligence」 生物科技初創公司。耀速創始團隊成員多來自於知名跨國生物醫藥企業及哈佛大學，麻省理工學院等頂尖科研院所，具有豐富的工業界醫藥產品開發和前沿生物與 AI 技術研發經驗。耀速正作為唯一一家中國公司和中美藥監機構聯合制定器官芯片全球首個行業標準。耀速科技與多家生物製藥公司和科研院所開展了戰略與科研合作。

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。

The China Automobile Dealers Association (CADA) released the latest Auto Consumption Index saying that the Auto Consumption Index stood at 74 in March, slightly higher than the previous month.

Following the market rebound, the auto market is expected to maintain its recovery momentum in April, with sales projected to inch up from March.
~


AASTOCKS Financial News
Website: www.aastocks.com

Global reach and diversified businesses continue to support growth

CHANGSHA, China, April 2, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion" or "the Company"; 1157.HK)  announced its 2025 annual results, reporting revenue of RMB 52.107 billion, up 14.58% year over year, and net profit attributable to shareholders of RMB 4.858 billion, up 38.01%. International revenue rose 30.52% to RMB 30.515 billion, accounting for 58.56% of total revenue, underscoring the growing role of the Company's global operations and broader business portfolio in supporting growth.

In 2025, Zoomlion continued to advance its core equipment businesses while scaling newer growth segments. Its concrete machinery, mobile crane machinery and construction hoisting machinery businesses all grew across international markets, with combined export sales rising more than 20% year over year.

Emerging businesses also contributed to growth. Revenue from earthmoving machinery increased by approximately 45% year over year, while international revenue from mining machinery rose more than threefold. The aerial work platform business continued to grow internationally, supported by localized operations including the launch of the Company's Hungary factory. Agricultural machinery also recorded international sales growth of more than 20%.

Robotics Portfolio Supports Future Growth

Zoomlion also continued to advance its robotics business, broadening its portfolio to include full-size wheeled humanoid robots, bipedal humanoid robots and quadruped robotic dogs. Multiple products have completed several rounds of iteration and entered the engineering stage.

Dozens of robots have been deployed in Zoomlion's smart factories for application validation in pre-assembly, sorting, material handling and quality inspection. The Company has also launched construction of a dedicated robot manufacturing facility as it moves toward small-batch production.

Global Footprint Continues to Strengthen

The Company's global footprint continued to deepen in 2025. Over the past four years, Zoomlion's international revenue has delivered a compound annual growth rate of 52%.

Zoomlion continues to strengthen its end-to-end, digitalized and localized direct-sales model in international markets. The Company now operates more than 430 international outlets and more than 220 service and spare parts warehouses, with products sold in over 170 countries and regions. Its international workforce exceeds 9,000 employees, including approximately 6,000 local hires, and its global manufacturing network now spans more than 10 bases across markets including Italy, Germany, Mexico, Brazil, Türkiye, the United States, Hungary and India.

With continued progress in globalization, business diversification and advanced technologies, Zoomlion continues to build a stronger foundation for long-term growth.

• 與安進合作探索靶向DLL3的ADC藥物zocilurtatug pelitecan聯合IMDELLTRA^®的臨床潛力
• 安進將申辦並執行一項全球1b期研究；再鼎醫藥保留zocilurtatug pelitecan的完整所有權

上海和馬薩諸塞州劍橋2026年4月2日 /美通社/ -- 再鼎醫藥有限公司（納斯達克代碼：ZLAB；香港聯交所股份代號：9688）今日宣佈與安進公司（納斯達克代碼：AMGN）達成一項全球臨床研究合作，旨在評估再鼎醫藥處於臨床階段的靶向delta樣配體3（DLL3）的抗體藥物偶聯物（ADC）zocilurtatug pelitecan（zoci，前稱ZL-1310）聯合安進IMDELLTRA^®（tarlatamab-dlle），一款靶向DLL3的雙特異性T細胞銜接器（BiTE^®）療法，用於治療廣泛期小細胞肺癌（ES-SCLC）患者。

作為該合作協議的一部分，安進將申辦一項全球1b期研究，評估zoci聯合IMDELLTRA^®在ES-SCLC患者中的安全性和有效性。再鼎醫藥將保留zoci的完整所有權，並將向安進提供臨床研究用藥。

再鼎醫藥總裁、全球研發負責人Rafael G. Amado博士表示：「這種雙靶向聯合策略有望提升全身及顱內治療的緩解率和緩解程度，應對耐藥機制，並為小細胞肺癌患者開闢新的治療範式。這兩種療法利用了互補的作用機制——我們的ADC將強效的細胞毒性載荷直接遞送至表達DLL3的腫瘤細胞，而T細胞銜接器則旨在通過結合同一抗原激活T細胞，引發抗腫瘤免疫應答。」

Zoci是靶向DLL3的 ADC，用於小細胞肺癌的治療。再鼎醫藥已在2025年EORTC-NCI-AACR（ENA）大會和2025年美國臨床腫瘤學會（ASCO）年會上公佈了zoci的1/2期臨床研究數據，數據顯示zoci在經過多藥治療的小細胞肺癌（SCLC）患者中實現了高緩解率，展示了顯著的顱內活性且可耐受的安全性。安進的IMDELLTRA^®已獲得FDA批准，目前在美國上市，用於治療既往接受含鉑化療後出現疾病進展的ES-SCLC成人患者。請參閱IMDELLTRA^®包括黑框警告在內的完整處方信息。

關於Zocilurtatug Pelitecan (zoci, 前稱ZL-1310)

Zoci是再鼎醫藥全球腫瘤研發管線中一款靶向DLL3的新型ADC。DLL3是一種在多個神經內分泌癌症中過度表達的抗原，是小細胞肺癌（SCLC）已驗證的治療靶點，通常與不良臨床預後相關。Zoci包含人源化抗DLL3單克隆抗體，該抗體與新型喜樹鹼衍生物（一種拓撲異構酶1抑制劑）連接作為其有效載荷。此分子的設計來源於新型ADC技術平台TMALIN^®。該平台能夠利用腫瘤微環境克服第一代ADC療法遇到的相關挑戰（包括脫靶載荷的毒性）。

Zoci正在進行全球臨床開發，涉及以下三項臨床研究方案：DLLEVATE研究——一項隨機三期關鍵性研究，旨在進一步評估zoci對比研究者選擇的單藥化療用於復發性ES-SCLC患者中的安全性和有效性；一項評估zoci用於包括肺外神經內分泌癌的特定實體瘤中的1b/2期研究；以及一項評估zoci單藥及聯合免疫檢查點抑制劑阿替利珠單抗用於ES-SCLC的1a/1b期研究。

Zoci的安全性特徵及明確的全身性和顱內的療效，支持其有望作為ES-SCLC一線聯合方案的基石，用以降低化療的毒性負擔。Zoci已獲得美國FDA授予的治療SCLC的孤兒藥資格認定和快速通道資格認定。

關於小細胞肺癌（SCLC）

小細胞肺癌是最具侵襲性和致命的實體腫瘤之一，每年全球約250萬被診斷為肺癌的患者中，大約有15%屬於小細胞肺癌^[1,2]。其中，約三分之二的小細胞肺癌患者在確診時已經處於廣泛期^[3]。該階段復發率高且預後差。ES-SCLC患者預後尤為嚴峻：初始治療後中位總生存期僅約12個月^[4]，五年總生存率約5-10%^[5]。一旦患者使用含鉑化療後出現疾病進展，可用的治療選擇曾經十分有限。IMDELLTRA^®是首款靶向DLL3的雙特異性T細胞銜接器療法，在上述患者中已驗證具有總生存期獲益。Zocilurtatug Pelitecan與IMDELLTRA^®的聯合用藥方案有望在此優勢基礎上，進一步改善有效性，同時保持可控的安全性^[6]。

關於再鼎醫藥

再鼎醫藥（納斯達克股票代碼：ZLAB； 香港聯交所股份代號：9688）是一家以研發為基礎、處於商業化階段的創新型生物製藥公司，總部位於中國和美國。我們致力於通過創新產品的發現、開發和商業化解決腫瘤、免疫、神經科學和感染性疾病領域未被滿足的巨大醫療需求。我們的目標是利用我們的能力和資源為人類健康帶來積極影響。

有關再鼎醫藥的更多信息，請訪問www.zailaboratory.com或關注https://x.com/ZaiLab_Global。

再鼎醫藥前瞻性聲明

本新聞稿包含關於再鼎醫藥未來預期、計劃和展望的前瞻性陳述，包括但不限於與我們開發和商業化包括zocilurtatug pelitecan在內的新一代抗體藥物偶聯物（ADC）相關的前景和計劃，zocilurtatug pelitecan的潛在獲益，以及小細胞肺癌和其他神經內分泌癌的潛在療法有關的陳述。這些前瞻性陳述可能包含諸如「旨在」、「預計」、「認為」、「可能」、「估計」、「預期」、「預測」、「目標」、「打算」、「或許」、「計劃」、「可能的」、「潛在」、「將會」、「將要」等詞語以及其他類似表述。此類陳述構成《1995年美國私人證券訴訟改革法案》所定義的前瞻性陳述。前瞻性陳述並非歷史事實的陳述，亦非對未來表現的擔保或保證。前瞻性陳述基於我們截至本新聞稿發佈之日的預期和假設，並且受到固有不確定性、風險以及可能與前瞻性陳述所預期的情況存在重大差異的情勢變更的影響。實際結果可能受各種重要因素的影響而與前瞻性陳述所示存在重大差異，該等因素包括但不限於：(1)我們成功商業化自身已獲批上市產品並從中產生收入的能力；(2)我們為自身的運營和業務活動獲取資金的能力；(3)我們候選產品的臨床開發和臨床前開發的結果；(4)相關監管機構對我們的候選產品作出審批決定的內容和時間；(5)與在中國營商有關的風險；和(6)我們向美國證券交易委員會（SEC）提交的最新年報和季報以及其他報告中指出的其他因素。我們預計後續事件和發展將導致我們的預期和假設改變，但除法律要求之外，不論是出於新信息、未來事件或其他原因，我們均無義務更新或修訂任何前瞻性陳述。該等前瞻性陳述不應被視為我們在本新聞稿發佈之日後任何日期的意見而加以信賴。

如需查閱公司向SEC提交的文件，請訪問公司網站www.zailaboratory.com和SEC網站www.SEC.gov。

According to Bloomberg, a US man on Tuesday (31st) filed a lawsuit in the US District Court for the Northern District of California, seeking to represent users of artificial intelligence startup Perplexity in a class action, alleging that the startup secretly shared users personal information with Meta (META.US) and Google under Alphabet (GOOGL.US), in suspected violation of California privacy laws.

The complaint alleges that once users log into Perplexity s homepage, a tracker is downloaded onto their devices, enabling Meta and Google to gain full access to conversations between users and Perplexity s AI-powered search engine. Even if users register and use Perplexity s "incognito" mode, their personal data is still shared. The filing further claims that "hard-to-detect" tracking software is embedded in the search engine s code, automatically transmitting user conversations to Meta, Google and other third parties. The plaintiff stated that he had shared information such as his household finances, taxes, investment portfolio and investment strategies with the Perplexity chatbot.

The complaint also names Meta and Google as defendants, alleging that both companies violated federal and state computer privacy and anti-fraud laws. (fc/u)~

AASTOCKS Financial News
Website: www.aastocks.com

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Cui Dongshu, Secretary-General of the China Passenger Car Association (CPCA), posted that, in 2026, lithium batteries, as an advantageous export category among China’s ‘New Trio’ products, maintained high growth rate prior to the reduction in export tax rebates. In 2M26, lithium battery exports reached US$14.2 billion, a 46% increase.

The EU will be the primary market for China’s lithium battery exports in 2026, with its market demand reaching around 43.1%, up 2.6 ppts YoY, according to market structure data.

Lithium battery exports to the US plummeted to 9.7%, marking a YoY decline of 6.4 ppts.
~

AASTOCKS Financial News
Website: www.aastocks.com

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

US President Donald Trump will address the nation at 9 pm Eastern Time on Wednesday to provide updates on the war with Iran. As market expectations for an end to the conflict continued to rise, US equities extended gains on Wednesday. The DJIA closed up 224 points or 0.5% at 46,565. The S&P 500 rose 46 points or 0.7%, closing at 6,575. The Nasdaq led the charge again, crossing the finish line at 21,840, up 250 points or 1.2%.

The rising likelihood of a US-Iran ceasefire mitigated fear of Iran’s threat to attack US technology firms operating in the Middle East. Alphabet (GOOG.US) grew 2.8%. Nvidia (NVDA.US) added 0.8%. Intel (INTC.US) surged nearly 9% after announcing that it will repurchase its stake in an Irish chip plant for USD14.2 billion. Tesla (TSLA.US) rallied 2.6%.
~


AASTOCKS Financial News
Website: www.aastocks.com

Liao Yixian, co-founder of Super Micro Computer (SMCI.US), pleaded not guilty on Wednesday at a hearing held in Manhattan, New York, to charges of assisting in the illegal transfer of Nvidia (NVDA.US) servers worth tens of billions of USD to China. The judge set the trial date for November 2.

US prosecutors last month charged Liao Yixian with violating US export controls by shipping high-performance computer servers assembled in the United States and equipped with Nvidia GPUs to China. Prosecutors allege that Liao Yixian and other company personnel sold the AI technology through a company in SE Asia, while knowing that the technology would ultimately be transshipped to China. Liao Yixian subsequently resigned from his position at Super Micro Computer.

(sw/t)~


AASTOCKS Financial News
Website: www.aastocks.com

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

US President Donald Trump said on Wednesday that Iranian President Masoud Pezeshkian has requested a ceasefire from the US side, but stressed that any proposal would only be considered after the Strait of Hormuz resumes free navigation. US stocks continued to advance on Wednesday. The DJIA rose 250 points, or 0.5%; the S&P 500 gained 43 points, or 0.7%, while the Nasdaq led the rally, climbing 240 points, or 1.1%.

Iran threatened to attack US technology companies operating in the Middle East. However, as the chances of a US-Iran ceasefire increased, Alphabet (GOOG.US) gained 2%, NVIDIA (NVDA.US) rose 1%, while Microsoft (MSFT.US) and Apple (AAPL.US) traded steadily.

Oil prices retreated and fell below USD100, pressuring energy stocks. Chevron (CVX.US) and Exxon Mobil (XOM.US) both dropped more than 4%.

Among earnings-related movers, Nike (NKE.US) slumped 14% after its North America revenue for the previous quarter missed expectations.

Trump is scheduled to address the nation at 9 p.m. Eastern Time on Wednesday to provide the latest update on the US-Iran war.

(me/t)~

AASTOCKS Financial News
Website: www.aastocks.com

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.